About this episode

This episode discusses a study comparing the IL17 inhibitor ixekizumab with the GLP1 inhibitor tirzepatide.

Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises some interesting questions about what worked here and whether or not it matters how it worked. Paper: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134 Newsletter: http://autoimmunedevreport.com/

Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.